Recombinant E.coli Classical Swine Fever
To Order Contact us: lieven@wlsolutions.be
Classical swine fever virus One-Step PCR kit |
||
| Oneq-V130-50R | 50T | EUR 1410 |
Recombinant (E.coli) Classical Swine Fever Virus E2 protein (CSFV-E2) (His-tag, >95%) purified |
||
| CSFE25-R-10 | 10 ug | EUR 416.4 |
Recombinant (E.coli) Classical Swine Fever Virus Erns protein (CSFV-Erns) (His-tag, >95%) purified |
||
| CSFR15-R-10 | 10 ug | EUR 416.4 |
Porcine/Swine/Pig Classical Swine Fever Virus (CSFV) E2 IgG negative control serum |
||
| AE-400200-01N | 1 ml | EUR 196.8 |
Porcine/Swine/Pig Classical Swine Fever Virus (CSFV) E2 IgG positive control serum |
||
| AE-400200-02P | 1 ml | EUR 270 |
Porcine/Swine/Pig Classical Swine Fever Virus (CSFV) Erns IgG negative control serum |
||
| AE-400210-03N | 1 ml | EUR 196.8 |
Porcine/Swine/Pig Classical Swine Fever Virus (CSFV) Erns IgG positive control serum |
||
| AE-400210-04P | 1 ml | EUR 270 |
Classical Swine Fever Virus Antibodies Rapid Test Kit (Colloidal gold) |
||
| abx092020-50tests | 50 tests | EUR 385.2 |
Classical Swine Fever Virus Antibody (IgG) (Human) ELISA Kit (OKCA01042) |
||
| OKCA01042 | 96 Wells | EUR 999.6 |
|
Description: Description of target: Classical Swine Fever Virus Antibody (IgG);Species reactivity: Human;Application: ;Assay info: Assay Methodology: Qualitative Reverse Capture ELISA;Sensitivity: |
||
Anti-Classical Swine Fever Virus E2 Antibody | MCSFV-5A-1G6 |
||
| MCSFV-5A-1G6 | 1.0 mg | EUR 712 |
|
Description: Anti-Classical Swine Fever Virus E2 Antibody | MCSFV-5A-1G6 | Immunology Consultants Laboratory Host: Mouse Format: Unconjugated AP Product Type: Primary Antibody Antibody Clonality: Monoclonal |
||
Anti-Classical Swine Fever Virus E2 Antibody | MCSFV-5A-2A11 |
||
| MCSFV-5A-2A11 | 1.0 mg | EUR 712 |
|
Description: Anti-Classical Swine Fever Virus E2 Antibody | MCSFV-5A-2A11 | Immunology Consultants Laboratory Host: Mouse Format: Unconjugated AP Product Type: Primary Antibody Antibody Clonality: Monoclonal |
||
Anti-Classical Swine Fever Virus E2 Antibody | MCSFV-5A-3G6 |
||
| MCSFV-5A-3G6 | 1.0 mg | EUR 712 |
|
Description: Anti-Classical Swine Fever Virus E2 Antibody | MCSFV-5A-3G6 | Immunology Consultants Laboratory Host: Mouse Format: Unconjugated AP Product Type: Primary Antibody Antibody Clonality: Monoclonal |
||
Rabbit anti-Classical Swine Fever Virus E2 protein (CSFV-E2) antiserum |
||
| CSFE21-S | 100 ul | EUR 548.4 |
Rabbit anti-Classical Swine Fever Virus Erns protein (CSFV-Erns) antiserum |
||
| CSFR11-S | 100 ul | EUR 548.4 |
Recombinant Classical Swine Fever Virus E2 protein (CSFV-E2) control for western blot |
||
| CSFE21-C | 100 ul | EUR 343.2 |
Recombinant Classical Swine Fever Virus Erns protein (CSFV-Erns) control for western blot |
||
| CSFR11-C | 100 ul | EUR 343.2 |
Recombivirus? Mouse Classical Swine Fever Virus (CSFV) E2 IgG ELISA kit, Quantitative, 96 tests |
||
| AE-400205-1 | 1 Kit | EUR 708 |
Recombivirus? Mouse Classical Swine Fever Virus (CSFV) E2 IgG ELISA kit, Quantitative, 5x96 tests |
||
| AE-400205-5 | 1 Kit | EUR 708 |
Recombivirus? Classical Swine Fever Virus (CSFV) E2 antigen coated plate for antibody ELISA (5x96 wells) |
||
| AE-400250-CP5 | 1 pk | EUR 927.6 |
Recombivirus? Classical Swine Fever Virus (CSFV) Erns antigen coated plate for antibody ELISA (5x96 wells) |
||
| AE-400255-CP5 | 1 pk | EUR 927.6 |
Swine Swine Fever Virus Antibody (CSFV-Ab) ELISA Kit |
||
| abx364798-96tests | 96 tests | EUR 651.6 |
African swine fever virus PCR kit |
||
| PCR-V121-48D | 50T | EUR 543.6 |
African swine fever virus PCR kit |
||
| PCR-V121-96D | 100T | EUR 686.4 |
Classical Porcine Fever Virus Total Antibody ELISA Kit |
||
| RK04110 | 96T | EUR 625.2 |
Classical Porcine Fever Virus Neutralizing Antibody ELISA Kit |
||
| RK04111 | 96T | EUR 625.2 |
Recombivirus? Mouse Classical Swine Fever Virus (CSFV) Erns IgG ELISA kit, Quantitative, 96 tests (DIVA Test) |
||
| AE-400215-1 | 1 Kit | EUR 708 |
Recombivirus? Mouse Classical Swine Fever Virus (CSFV) Erns IgG ELISA kit, Quantitative, 5x96 tests (DIVA Test) |
||
| AE-400215-5 | 1 Kit | EUR 708 |
African swine fever virus RT PCR kit |
||
| RTq-V121-100D | 100T | EUR 860.4 |
African swine fever virus RT PCR kit |
||
| RTq-V121-150D | 150T | EUR 969.6 |
African swine fever virus RT PCR kit |
||
| RTq-V121-50D | 50T | EUR 717.6 |
Recombinant (E. coli) African Swine fever virus (ASFV) protein |
||
| ASFV15-R-10 | 10 ug | EUR 416.4 |
Rabbit Anti-Pig/Swine Anti-African Swine fever virus (ASFV) IgG antiserum |
||
| ASFV11-S | 100 ul | EUR 548.4 |
Pig/Swine Anti-African Swine fever virus (ASFV) IgG negative control serum |
||
| RV-500900-01N | 1 ml | EUR 196.8 |
Pig/Swine Anti-African Swine fever virus (ASFV) IgG positive control serum |
||
| RV-500900-02P | 1 ml | EUR 270 |
African swine fever virus One-Step PCR kit |
||
| Oneq-V121-100D | 100T | EUR 1039.2 |
African swine fever virus One-Step PCR kit |
||
| Oneq-V121-150D | 150T | EUR 1177.2 |
African swine fever virus One-Step PCR kit |
||
| Oneq-V121-50D | 50T | EUR 861.6 |
Recombinant African Swine fever virus (ASFV) P30 protein control for western blot |
||
| ASFV11-C | 100 ul | EUR 343.2 |
Recombinant (E.coli) Swine/Porcine Parvovirus (PPV) NS1 protein |
||
| PPVNS15-R-10 | 10 ug | EUR 416.4 |
Recombinant (E.coli) Swine/Porcine Parvovirus (PPV) VP2 protein |
||
| PPVVP25-R-10 | 10 ug | EUR 416.4 |
Swine CCL2 Recombinant Protein |
||
| R00056-5 | 5ug/vial | EUR 310.8 |
|
Description: Chemokine (C-C motif) ligand 2 (CCL2), also known as monocyte chemotactic protein-1 (MCP-1), is a small cytokine belonging to the CC chemokine family. CCL2 (MCP-1) recruits monocytes, memory T cells, and dendritic cells to sites of tissue injury and infection. Swine CCL2 (MCP-1) Recombinant Protein is purified CCL2 (MCP-1) produced in yeast. |
||
Swine CXCL10 Recombinant Protein |
||
| R00278-8 | 5ug/vial | EUR 310.8 |
|
Description: The ELR-negative CXC chemokine CXCL10 (IP-10) has been attributed to several roles, such as chemoattraction for monocytes/macrophages, T cells, NK cells, and dendritic cells, promotion of T cell adhesion to endothelial cells, antitumor activity, and inhibition of bone marrow colony formation and angiogenesis. Swine CXCL10 Recombinant Protein is purified CXCL10 (IP-10) produced in yeast. |
||
Swine EPO Recombinant Protein |
||
| R00484-2 | 5ug/vial | EUR 310.8 |
|
Description: Erythropoietin (EPO) is an essential hormone for red blood cell production. Erythropoietin has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers. Swine Erythropoietin Recombinant Protein is purified Erythropoietin (EPO) produced in yeast. |
||
Swine CCL5 Recombinant Protein |
||
| R00617-4 | 5ug/vial | EUR 310.8 |
|
Description: CCL5, also known as RANTES (regulated and normal T cell expressed and secreted), is a member of the C-C Chemokine Family. RANTES (CCL5) is chemotactic for T cells, eosinophils, and basophils, and plays an active role in recruiting leukocytes into inflammatory sites. Swine CCL5 Recombinant Protein is purified CCL5 (RANTES) produced in yeast. |
||
Swine CCL4 Recombinant Protein |
||
| R00703-7 | 5ug/vial | EUR 310.8 |
|
Description: The small chemotactic cytokine CCL4 (MIP-1 beta) is a chemoattractant for natural killer cells, monocytes and a variety of other immune cells. CCL4 is involved in several inflammatory and autoimmune diseases including viral infection such as HIV-1/AIDS. Swine CCL4 Recombinant Protein is purified chemokine ligand 4 (CCL4, MIP-1 beta) produced in yeast. |
||
Swine CCL20 Recombinant Protein |
||
| R00748-1 | 5ug/vial | EUR 310.8 |
|
Description: Chemokine ligand 20 (CCL20), also known as liver activation regulated chemokine (LARC) or Macrophage Inflammatory Protein-3 (MIP3A), is strongly chemotactic for lymphocytes. CCL20 elicits its effects on its target cells by binding and activating the chemokine receptor CCR6. Swine CCL20 Recombinant Protein is purified CCL20 (LARC, MIP3A) produced in yeast. |
||
Swine CD40LG Recombinant Protein |
||
| R01114-2 | 5ug/vial | EUR 310.8 |
|
Description: CD40 Ligand (CD40LG) is a transmembrane protein that is a member of the TNF superfamily. In addition to existing in a membrane bound form, CD40LG can also be released as a soluble molecule (sCD40LG), which has been shown to have biological functions.CD40 interacts with CD40 ligand (aka CD40LG, TNFSF5 or CD154), which is predominantly expressed on activated CD4+ T-cells. Swine CD40 Ligand Recombinant Protein is purified CD40LG produced in yeast. |
||
Swine BAFF Recombinant Protein |
||
| R01257-5 | 5ug/vial | EUR 310.8 |
|
Description: BAFF (B-cell Activation Factor), also known as Tumor Necrosis Factor Superfamily member 13B (TNFSF13B), is expressed in B cell lineage cells and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. Swine BAFF Recombinant Protein is purified b-cell activation factor produced in yeast. |
||
Swine CXCL9 Recombinant Protein |
||
| R01397-6 | 5ug/vial | EUR 310.8 |
|
Description: CXCL9 (MIG) is a T-cell chemoattractant. Induced by IFN-gamma (IFN-γ), the ELR-negative chemokine CXCL9 (MIG) elicits its effects by binding to the cell surface chemokine receptor CXCR3. Swine CXCL9 Recombinant Protein is purified CXCL9 (MIG) produced in yeast. |
||
Swine CXCL11 Recombinant Protein |
||
| R01833-1 | 5ug/vial | EUR 310.8 |
|
Description: Chemokine (C-X-C motif) ligand 11 (CXCL11) is a small, interferon-inducible cytokine belonging to the CXC chemokine family. Along with homologous ELR-negative CXC chemokines CXCL9 (MIG) and CXCL10 (IP-10), CXCL11 facilitates selective recruitment of mononuclear leukocytes, natural killer cells, and plasmacytoid dendritic cells to sites of inflammation. Swine CXCL11 Recombinant Protein is purified CXCL11 produced in yeast. |
||
Swine TWEAK Recombinant Protein |
||
| R02009-1 | 5ug/vial | EUR 310.8 |
|
Description: TNF-related weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor (TNF) ligand family (TNFSF12). TWEAK can induce apoptosis via multiple pathways of cell death in a cell type-specific manner. TWEAK is also found to promote proliferation and migration of endothelial cells, and thus acts as a regulator of angiogenesis. Swine TWEAK (TNFSF12) Recombinant Protein is purified TWEAK (TNFSF12) produced in yeast. |
||
Swine APRIL Recombinant Protein |
||
| R02417-5 | 5ug/vial | EUR 310.8 |
|
Description: A proliferation-inducing ligand (APRIL), also known as TNFSF13, is a member of the tumor necrosis factor (TNF) ligand superfamily. APRIL/TNFSF13 has been shown to play a role in protecting cells from undergoing apoptosis and promoting B cell development. Swine APRIL Recombinant Protein is purified APRIL (TNFSF13) produced in yeast. |
||
Swine CCL3L1 Recombinant Protein |
||
| R11820 | 5ug/vial | EUR 310.8 |
|
Description: CCL3L1, Chemokine (C-C motif) Ligand 3-Like 1, binds to several chemokine receptors including chemokine binding protein 2 (CCBP2) and CC chemokine receptor 5 (CCR5). Swine CCL3L1 Recombinant Protein is purified chemokine (C-C motif) ligand 3-like 1 produced in yeast. |
||
Swine TNF alpha Recombinant Protein |
||
| R00002-11 | 5ug/vial | EUR 310.8 |
|
Description: Tumor necrosis factor alpha (TNFSF2, TNF alpha) is a member of the TNF Superfamily. TNF alpha, being an endogenous pyrogen, is able to induce fever, to induce apoptotic cell death, to induce sepsis (through IL-1 & IL-6 production), to induce cachexia, induce inflammation, and to inhibit tumorigenesis and viral replication. Swine TNF alpha Recombinant Protein is purified TNF alpha (TNFSF2) produced in yeast. |
||
Swine IL-10 Recombinant Protein |
||
| R00021-4 | 5ug/vial | EUR 310.8 |
|
Description: IL-10 is an anti-inflammatory cytokine and a member of the IL-10 family of cytokines, which have indispensable functions in many infectious and inflammatory diseases. Swine IL-10 Recombinant Protein is purified interleukin-10 produced in yeast. |
||
Swine VEGF-A Recombinant Protein |
||
| R00045-8 | 5ug/vial | EUR 310.8 |
|
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Swine VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast. |
||
Swine IL-13 Recombinant Protein |
||
| R00077-5 | 5ug/vial | EUR 310.8 |
|
Description: IL-13 is an important mediator of allergic inflammation and disease. In addition to effects on immune cells, IL-13 is implicated as a central mediator of the physiologic changes induced by allergic inflammation in many tissues. Swine IL-13 Recombinant Protein is purified interleukin-13 produced in yeast. |
||
Swine IL-6 Recombinant Protein |
||
| R00102-8 | 5ug/vial | EUR 310.8 |
|
Description: Interleukin-6 (IL-6) is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. Swine IL-6 Recombinant Protein is purified interleukin-6 produced in yeast. |
||
Swine IL-15 Recombinant Protein |
||
| R00212-3 | 5ug/vial | EUR 310.8 |
|
Description: Interleukin-15 (IL-15) is a cytokine with structural similarity to IL-2 that is secreted by mononuclear phagocytes following infection by virus(es). This cytokine induces cell proliferation of natural killer cells. Swine IL-15 Recombinant Protein is purified interleukin-15 produced in yeast. |
||
Swine IL-4 Recombinant Protein |
||
| R00230-8 | 5ug/vial | EUR 310.8 |
|
Description: IL-4 has many biological roles, including the stimulation of activated B-cell and T-cell proliferation, and the differentiation of CD4+ T-cells into Th2 cells. It is a key regulator in humoral and adaptive immunity. Swine IL-4 Recombinant Protein is purified interleukin-4 produced in yeast. |
||
Swine IL-2 Recombinant Protein |
||
| R00387-9 | 5ug/vial | EUR 310.8 |
|
Description: Interleukin-2 (IL-2) is a cytokine produced by T-helper cells in response to antigenic or mitogenic stimulation. It is required for T-cell proliferation and other activities crucial to the regulation of the immune response. Swine IL-2 Recombinant Protein is purified interleukin-2 produced in yeast. |
||
Swine IFN gamma Recombinant Protein |
||
| R00393-11 | 5ug/vial | EUR 310.8 |
|
Description: IFN-gamma, or type II interferon, is a cytokine that is critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. Swine IFN gamma Recombinant Protein is purified IFN gamma produced in yeast. |
||
Swine IL-17A Recombinant Protein |
||
| R00421-8 | 5ug/vial | EUR 310.8 |
|
Description: IL-17A is a member of the IL-17 family of cytokines, whose members are involved in numerous immune regulatory functions. IL-17 induces the production of many other cytokines, chemokines, and prostaglandins. Swine IL-17A Recombinant Protein is purified interleukin-17A produced in yeast. |
||
Swine IL-8 Recombinant Protein |
||
| R00423-11 | 5ug/vial | EUR 310.8 |
|
Description: Interleukin-8 (IL-8), also known as CXCL8, is an ELR-positive CXC family member chemokine produced by macrophages and other cell types such as epithelial cells. ELR-positive CXC chemokines such as IL-8 specifically induce the migration of neutrophils, and interact with chemokine receptors CXCR1 and CXCR2. Swine IL-8 Recombinant Protein is purified interleukin-8 produced in yeast. |
||
Swine IL-21 Recombinant Protein |
||
| R00459-4 | 5ug/vial | EUR 310.8 |
|
Description: The cytokine interleukin-21 (IL-21) regulates the proliferation and differentiation of T and B lymphocytes, modulates the cytotoxic activity and survival of NK and CD8+ T cells, and suppresses the maturation of dendritic cells. Swine IL-21 Recombinant Protein is purified interleukin-21 produced in yeast. |
||
Swine IL-1ra Recombinant Protein |
||
| R00651-5 | 5ug/vial | EUR 310.8 |
|
Description: Interleukin-1 Receptor Antagonist Protein (IL-1F3, IL-1ra) belongs to the IL-1 family of cytokines, whose members play key roles in the development and regulation of inflammation. IL-1 receptor antagonist (IL-1ra; IL-1F3) reduces inflammation by blocking the binding of the agonist receptor ligands. Swine IL-1 Receptor Antagonist Recombinant Protein is purified interleukin-1 receptor antagonist protein (IL-1F3, IL-1ra) produced in yeast. |
||
Swine GM-CSF Recombinant Protein |
||
| R00911-7 | 5ug/vial | EUR 310.8 |
|
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a protein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Swine GM-CSF Recombinant Protein is purified GM-CSF produced in yeast. |
||
Swine IL-22 Recombinant Protein |
||
| R00963-2 | 5ug/vial | EUR 310.8 |
|
Description: IL-22 is produced by activated DC, T cells, splenic cells, and Th17 cells, and it initiates innate immune responses against bacterial pathogens, especially in epithelial cells such as respiratory and gut epithelial cells. Swine IL-22 Recombinant Protein is purified interleukin-22 produced in yeast. |
||
Swine IFN beta Recombinant Protein |
||
| R02041-3 | 5ug/vial | EUR 310.8 |
|
Description: IFN beta is a mammalian Type I interferon, functioning as a regulator of cellular activity by interacting with cell-surface receptors and activating various signaling pathways. IFN beta produces antiviral, antibacterial, and anticancer properties. Swine IFN beta Recombinant Protein is purified IFN beta produced in yeast. |
||
Swine IL-17F Recombinant Protein |
||
| R02062-2 | 5ug/vial | EUR 310.8 |
|
Description: IL-17F induces the production of many other cytokines, chemokines, and prostaglandins from many cell types (fibroblasts, endothelial cells, epithelial cells, keratinocytes and macrophages). IL-17F has been shown to have a pro-inflammatory role in asthma. Swine IL-17F Recombinant Protein is purified interleukin-17F produced in yeast. |
||
Swine Elastase Antibody |
||
| 20271-05011 | 150 ug | EUR 260.4 |
Swine Albumin Antibody |
||
| 12004-05011 | 150 ug | EUR 260.4 |
Swine Haptoglobin Antibody |
||
| 15771-05011 | 150 ug | EUR 260.4 |
Swine Prothrombin Antibody |
||
| 25887-05011 | 150 ug | EUR 260.4 |
Goat Swine IgG |
||
| A21090-01ml | 0.1ml | EUR 92.4 |
|
Description: A polyclonal antibody for detection of Goat Swine IgG from Swine. This Goat Swine IgG antibody is for WB, IHC-P, ELISA. It is Affinity purified using solid phase Swine IgG (H&L) with finally > 95% purity based on SDS-PAGE and conjugated to HRP. The antibody is produced in goat by using as an immunogen Swine IgG whole molecule |
||
Goat Swine IgG |
||
| A21090-05ml | 0.5ml | EUR 189.6 |
|
Description: A polyclonal antibody for detection of Goat Swine IgG from Swine. This Goat Swine IgG antibody is for WB, IHC-P, ELISA. It is Affinity purified using solid phase Swine IgG (H&L) with finally > 95% purity based on SDS-PAGE and conjugated to HRP. The antibody is produced in goat by using as an immunogen Swine IgG whole molecule |
||
Swine IL-1 beta Recombinant Protein |
||
| R00101-10 | 5ug/vial | EUR 310.8 |
|
Description: IL-1 beta (IL-1β) is a member of the interleukin 1 family of cytokines. The IL-1 beta cytokine is produced by activated macrophages as a proprotein, which is proteolytically processed to its active form by caspase 1 (CASP1/ICE). This cytokine is an important mediator of the inflammatory response, and is involved in a variety of cellular activities, including cell proliferation, differentiation, and apoptosis. Swine IL-1 beta Recombinant Protein is purified interleukin-1 beta cytokine produced in yeast. |
||
Swine IL-12 p40 Recombinant Protein |
||
| R01152-3 | 5ug/vial | EUR 310.8 |
|
Description: The IL-12 p40 subunit, or interleukin-12 beta subunit, is the 40 kD cytokine receptor-like subunit of the heterodimeric cytokines IL-12 and IL-23. IL-12 is involved in the differentiation of naive T cells into Th1 cells and the growth and function of T cells. Both IL-23 and IL-12 can activate the transcription activator STAT4 and stimulate the production of interferon-gamma (IFNG). Swine IL-12 p40 Recombinant Protein is purified interleukin-12 p40 produced in yeast. |
||
Swine IFN alpha 1 Recombinant Protein |
||
| R09608-4 | 5ug/vial | EUR 310.8 |
|
Description: IFN alpha is a mammalian Type I inferferon, mainly involved in innate immune response against viral infection. Swine IFN alpha 1 Recombinant Protein is purified IFN alpha produced in yeast. |
||
Recombinant (E.coli) Swine/Porcine Parvovirus (PPV) NS1 protein control for western blot |
||
| PPVNS11-C | 100 ul | EUR 343.2 |
Recombinant (E.coli) Swine/Porcine Parvovirus (PPV) VP2 protein control for western blot |
||
| PPVVP21-C | 100 ul | EUR 343.2 |
Recombinant yellow fever virus Env protein |
||
| DAG832 | 1 mg | EUR 858 |
Swine H1N1 Hemagglutinin Antibody |
||
| 5233-002mg | 0.02 mg | EUR 206.18 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. This antibody is specific for the novel swine influenza Hemagglutinin and will not recognize the corresponding Hemagglutinin sequence from the seasonal H1N1 influenza (A/Brisbane/59/2007 (H1N1)). |
||
Swine H1N1 Hemagglutinin Antibody |
||
| 5233-01mg | 0.1 mg | EUR 523.7 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. This antibody is specific for the novel swine influenza Hemagglutinin and will not recognize the corresponding Hemagglutinin sequence from the seasonal H1N1 influenza (A/Brisbane/59/2007 (H1N1)). |
||
Swine H1N1 Hemagglutinin Peptide |
||
| 5233P | 0.05 mg | EUR 197.7 |
|
Description: Swine H1N1 Hemagglutinin peptide |
||
Swine H1N1 Hemagglutinin Antibody |
||
| 5237-002mg | 0.02 mg | EUR 206.18 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Hemagglutinin Antibody |
||
| 5237-01mg | 0.1 mg | EUR 523.7 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Hemagglutinin Peptide |
||
| 5237P | 0.05 mg | EUR 197.7 |
|
Description: Swine H1N1 Hemagglutinin peptide |
||
Swine H1N1 Hemagglutinin Antibody |
||
| 5241-002mg | 0.02 mg | EUR 206.18 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Hemagglutinin Antibody |
||
| 5241-01mg | 0.1 mg | EUR 523.7 |
|
Description: Swine H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Hemagglutinin Peptide |
||
| 5241P | 0.05 mg | EUR 197.7 |
|
Description: Swine H1N1 Hemagglutinin peptide |
||
Swine H1N1 Neuraminidase Antibody |
||
| 5249-002mg | 0.02 mg | EUR 206.18 |
|
Description: Swine H1N1 Neuraminidase Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Neuraminidase Antibody |
||
| 5249-01mg | 0.1 mg | EUR 523.7 |
|
Description: Swine H1N1 Neuraminidase Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
||
Swine H1N1 Neuraminidase Peptide |
||
| 5249P | 0.05 mg | EUR 197.7 |
|
Description: Swine H1N1 Neuraminidase peptide |
||
Swine/Rat Galanin Antibody |
||
| 10881-05011 | 150 ug | EUR 260.4 |
Swine H1N1 Hemagglutinin Antibody |
||
| 24918-100ul | 100ul | EUR 468 |